Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
617 A Phase I study of a tumor-targeted, fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.